Yingli Pharma has received FDA approval for Phase III trial of linperlisib for R/R PTCL. The global trial, set to start in the second quarter, aims to evaluate the drug's efficacy against standard care for patients who have undergone prior systemic therapies.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing